Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia
Background: Real-world data suggests superiority of pegfilgrastim (PEG) over filgrastim (FIL) in reducing the incidence of chemotherapy-induced febrile neutropenia (FN), probably attributable to underdosed FIL in practice. We used real-world data to assess the cost-effectiveness of primary prophylax...
Main Authors: | Cornes, P. (Author), Kelton, J. (Author), Liu, R. (Author), Stephens, J. (Author), Yang, J. (Author), Zaidi, O. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Future Medicine Ltd.
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
A Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy
by: Roberto Ravasio, et al.
Published: (2020-03-01) -
Modelling chemotherapy effects on granulopoiesis
by: Schirm, Sibylle, et al.
Published: (2015) -
Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
by: Choi C, et al.
Published: (2018-08-01) -
Biosimilars in the management of neutropenia: focus on filgrastim
by: Caselli D, et al.
Published: (2016-02-01) -
Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
by: Otremba B, et al.
Published: (2018-10-01)